The role of metronidazole in COVID-19

Evaluation of therapeutic effects of Metronidazole In Inpatients with Pneuomonia Due to COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200608047686N1

Enrollment

Registered

2020-06-30

Start date

2020-05-31

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: 15 eligible patients with moderate to severe COVID-19 in a 1:1 ratio compared to the control group who receive 250 mg metronidazole tablets orally every 6 hours fo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inpatients with Pneuomonia Due to COVID-19

Exclusion criteria

Exclusion criteria: Hypersensitivity Reactions to Metronidazole Pregnancy

Design outcomes

Primary

Measure	Time frame
O2 Saturation. Timepoint: within 7 days from initiation of study treatmentat. Method of measurement: Pulse Oximetry.	—

Secondary

Measure	Time frame
Mortality. Timepoint: daily up to death during hospitalizatiion. Method of measurement: Patient death.;Lenght of hospitat stay. Timepoint: daily up to discharge. Method of measurement: Inpatient days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMuhanna Kazempour

Shahid Beheshti University of Medical Sciences

muhannakazempour@gmail.com+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026